The FDA has approved a once-daily tablet combining amlodipine drags (Norvasc), a calcium-channel blocker, and olmesartan medoxomil (Benicar), an angio-tensin-receptor blocker, for the treatment of hypertension drags. In clinical trials, Azor pro duced significant mean reductions in systolic and diastolic blood pressure. When compared with generic amlodipine 10 mg alone, Azor 10/40 mg resulted in a 53% greater reduction in systolic blood pressure.
Azor is indicated for the treatment of generic hypertension alone or with other anti hypertensive agents. It is not indicated as initial therapy for hypertension.
Source: Daiichi Sankyo, September 27, 2007